Parkinson's disease (PD) is a common neurodegenerative disease characterized by dopaminergic cell death and deposition of Lewy bodies within the substantia nigra of the midbrain. Although the major risk factors for PD are aging and environmental factors, there is an important genetic component. An age-related change in xenobiotic metabolism alters the metabolism of and net exposure to, environmental neurotoxins. Genetic variability in xenobiotic metabolism may similarly increase the susceptibility to PD by altering the metabolism of neurotoxins. Genetic studies of rare familial cases of PD indicate a central mechanistic role for the aggregation of alpha-synuclein, a protein found in Lewy bodies. Environmental factors like pesticides and heavy metals can also influence alpha-synuclein aggregation. Common final pathways for aging, environmental, and genetic mechanisms can thus exist, involving both direct neurotoxicity and alpha-synuclein aggregation.
INTRODUCTION
Parkinson's disease (PD) is a common neurodegenerative disorder having a prevalence of approximately 1 % to 4% of the adult population in the Western world /1,2/. The lifetime risk of developing PD from birth is 4.4% for males and 3.7% for females ß/. PD is predominantly a disease of older people, with an average age of onset of 60 years l\l. The disease is characterized clinically by a triad of features: resting tremor, muscle rigidity, and bradykinesia. The disease is slowly progressive and as yet, all treatments are primarily symptomatic with little if any effect on disease progression.
The signs and symptoms are mechanistically linked to the depletion of the neurotransmitter dopamine in the corpus striatum. This, in turn, is secondary to the loss of dopaminergic neurons in the pars compacta of the substantia nigra. These neurons contain a black pigment, neuromelanin, and loss of this pigment from the substantia nigra is the classic pathological finding in PD. In addition, Lewy bodies, intracytoplasmic inclusion bodies 52 D.G. LE COUTEUR ET AL.
containing ubiquitin and alpha-synuclein, are seen within the remaining dopaminergic neurons. Brain tissue analysis demonstrated that PD is associated with oxidative stress, glutathione depletion, and mitochondrial dysfunction, specifically impaired complex I activity /4, 5/.
The etiology of PD remains unclear. In the original description of PD by James Parkinson, "An essay on the shaking palsy" (1817), alcoholism, caffeine, senility, or space-occupying lesions were excluded as causes of the tremor in each subject, but Parkinson himself was not able to proffer any other possible causes 161. During the earlier part of the 20 th Century, arteriosclerosis and von Economo's encephalitis were considered to be implicated in PD 111. During the last 20 years, a dramatic increase has occurred in understanding the etiology of PD, focusing on both genetic /8, 9/ and neurotoxic mechanisms /10-12/.
GENETIC MECHANISMS

Familial PD
A familial component for PD has been recognized for over a century /13/. Many casecontrol studies have been performed showing that the risk of PD to first-degree relatives of patients is significantly increased. The odds ratios vary from 2-to 15-fold, and about 10% to 30% of subjects with PD have an affected first-degree relative /13/. In Australia, we found that among patients, 19% had a positive family history and 11% had a firstdegree relative with PD compared with 6% and 5%, respectively, in unaffected controls /1 /.
Several twin studies have yielded conflicting results. The largest twin study examined 19,842 white male twins enrolled in the World War II Veteran Twins Registry /14/. The similar overall concordance between monozygotic and dizygotic twins in that study suggests the absence of a genetic component after the age of 50. Conversely, in 16 pairs of twins in whom the age of onset was before 50 years, concordance was greater in monozygotic than in dizygotic twins, indicative of a genetic component in early-onset PD. Moreover, a twin study on sporadic PD, using positron emission tomography to examine striatal dopaminergic activity, concluded that progressive loss of dopaminergic function is more commonly concordant in monozygotic twin pairs than in dizygotics (55% versus 18%, respectively)/15/.
A study of the genealogy of over 600,000 people in Iceland over 11 centuries attempted to determine a possible hereditary component in PD /16/. A diagnosis of Parkinson's disease was confirmed in 772 living and deceased subjects, in whom the disease had been diagnosed during the previous 50 years. Subjects with PD were significantly more related to each other than were subjects in matched groups of controls. The relative risk of developing PD was 6.7 for siblings, 3.2 for offspring, and 2.7 for nephews and nieces of subjects with late-onset Parkinson's disease. The authors concluded that both genetic and environmental factors influence PD susceptibility.
Additionally, in several families, PD follows classic Mendelian autosomal dominant or recessive inheritance. Genetic analysis of these families has provided considerable insight into the pathogenesis of idiopathic PD/9, 13, 17, 18/.
Alpha-Synuclein (SNCA)
A study of the Contursi kindred with early onset parkinsonism and autosomal dominant inheritance revealed that a single nucleotide alteration within the alpha-synuclein gene (SNCA) was causative /19/. This mutation probably has a single founder and has been excluded in studies of other families and subjects with PD 19, 201 . A second point mutation in SNCA was identified in a German family with PD/21/.
Although a mutation in SNCA is a rare cause of PD, the alpha-synuclein protein is more broadly involved in the pathogenesis of PD. Alpha-synuclein is a pre-synaptic protein whose normal function is unknown. Alpha-synuclein is found in Lewy bodies and aggregation of alpha-synuclein-whether induced by genetic abnormalities, xenobiotics, or oxidative stress-is thought to be a central process leading to death of dopaminergic cells 191.
Parkin
Deletions and point mutations in the parkin gene have been described in a number of Japanese families with early onset, Lewy body-negative parkinsonism and autosomal recessive inheritance 1221. Various mutations in the parkin gene are associated with about 50% of early-onset PD cases 123) 1 Although the MPTP model is widely accepted as an experimental model for the study of nigral degeneration, it does not replicate certain aspects of PD seen in humans. MPTP toxicity in humans and other species is sub-acute and non-progressive. MPTP or similar compounds have not been found in the brain or the body fluids of subjects with PD /36/, nor is there a history of exposure to MPTP in most PD subjects. On the other hand, inclusion bodies have been detected in the brain of older non-human primates treated with MPTP /37/. Although MPTP itself is unlikely to be the cause of PD, epidemiological evidence has established the possibility of, and a prototype for, a neurotoxic etiopathogenesis /38-40/.
The disposition and mechanisms of action of MPTP have been investigated. We found that MPTP is highly extracted by the liver and has low bioavailability /41/, and that the uptake of MPTP into the liver is mostly by simple diffusion with a small fraction via the organic cation transporter (OCT1) and possibly P-glycoprotein /42/. MPTP is metabolized by flavin mono-oxygenases (FMO) and cytochrome P450 2D6 to non-toxic metabolites /43/. MPTP that escapes hepatic metabolism crosses the blood brain barrier because it is lipophilic and is converted to l-methyl-4-phenylpyridinium (MPP 1 ) by monoamine oxidase Β (MAOB) within glial cells. MPP + is a toxic metabolite that is taken up by dopaminergic cells by the dopamine transporter, with this uptake process conferring toxicity specifically to dopaminergic cells. Once within the dopaminergic neurons, MPP f causes cell death through inhibition of complex I of the mitochondrial electron transfer chain /3 8/.
The discovery of the association between MPTP and PD was a landmark discovery, providing many animal models for the study of PD and its treatment, as well as focusing research on toxic factors and mitochondrial dysfunction in its pathogenesis.
Rotenone
Betarbet et al. /44/ reported that chronic administration of rotenone to rats leads to nigrostriatal dopaminergic degeneration associated with hypokinesia and rigidity. Furthermore, fibrillar cytoplasmic inclusions that develop within nigral neurons contain ubiquitin and alpha-synucleinhence similar to Lewy bodies. Rotenone is a lipophilic pesticide that non-selectively inhibits complex 1 of the mitochondrial electron transfer chain /44/.
Pesticides and Environmental Factors
Primarily, the discovery of MPTP-induced parkinsonism was the incentive for undertaking epidemiological studies to determine whether environmental toxins, perhaps similar to MPTP, are implicated in the pathogenesis of PD. Although industrial or laboratory exposure to MPTP has been associated with parkinsonism /31, 45/, MPTP and/or related substances could not be not found in the brain of subjects with PD /36/.
MPP+, the toxic metabolite of MPTP, had been produced as an herbicide (Cyperquat), and MPTP has some structural similarity to another extensively used herbicide, paraquat. Consequently, many investigators have searched for associations between pesticide exposure and PD. In a recent systematic review of pesticides and PD, we found 20 published case-control studies across several continents investigating the association between pesticide exposure and PD. Twelve studies reported a positive association with odds ratios varying between 1.8 and 7 /10/. Of these, two reports found an association between paraquat exposure and PD /46, 47/. In addition, we noted six individual case reports of parkinsonian syndromes following exposure to pesticides, including organophosphates, paraquat, diquat, and maneb /10/. Subsequently, a meta-analysis^ of 19 studies that were published between 1989 and 1999 detected significant heterogeneity /48/. The combined odds ratio for PD associated with pesticide exposure was 1.94 (95% CI 1.49-2.53) for all the studies, and 2.15 (95% CI 1.14^.05) for those from the United States. Risk of PD increased with duration of exposure to pesticides, but no dose-response relation was established, nor was any specific type of pesticide identified /48/.
Since these two reviews, additional reports have been published linking pesticide exposure with PD. A case-control study from Israel found an association between pesticide exposure and construction site work among 93 subjects with PD and their matched controls /49/. A case-control study of 215 subjects with PD and 313 controls in a Hong Kong Chinese population found that pesticide exposure was associated with a slightly increased risk of PD (OR 1.05, 95%CI 1.01-1.09) but with greater risk in women (OR 6.84, 95%CI 1.90-24.7) /50/. Mortality associated with PD was significantly higher in Californian counties with high pesticide usage than in those having lower usage /51/. A study of over 2 million subjects in Denmark found that a high risk of PD, determined by hospitalization, occurred in fanners and in men involved in agriculture and horticulture, occupations clearly associated with pesticide exposure /52/. A case series has been reported of five subjects who developed acute and reversible parkinsonism following suicidal and home fumigation exposure to various organophosphates /53/. Other recent epidemiological studies, however, did not find an association between PD and pesticide exposure /54, 55/.
Organochlorine pesticides have been detected in the brain of individuals with PD. Traces of dieldrin were found in 6 of 29 PD brains but in none of 14 control samples. /56/. In another study, levels of lindane and dieldrin were significantly higher in PD brains than in controls or subjects with AD /57/. Organochlorine pesticides are poorly biodegradable, therefore the results of these studies may indicate past exposure to pesticides in general rather than to organochlorines specifically /10/.
Besides pesticides, several other environmental risk factors have been investigated. Smoking is consistently associated with reduced risk of PD, and a recent meta-analysis suggested that the risk is reduced by approximately 50% /58/. Other risk factors are less certain. In a meta-analysis, the combined odds ratio for rural residence was 1. Together, all these observations suggest that environmental factors like pesticides and the rare but important genetic causes of PD may have a common final mechanism involving the aggregation of alpha-synuclein, which leads to dopaminergic cell death and, in some cases, to Lewy body formation.
AGING AND AGE-ENVIRONMENT
INTERACTIONS
Despite the considerable interest in the role of environmental and genetic factors in the pathogenesis of PD, the major risk factor for PD (as for many diseases) is old age. The average age of onset of PD is about 60 years /!/, and both prevalence and incidence increase almost exponentially with each decade of life 111.
Many mechanisms for this association are possible. For example, processes linked to aging biology, such as oxidative stress and mitochondrial dysfunction, are clearly associated with PD, and PD has been suggested to be merely a feature of aging. On the other hand, any changes in the number and distribution of dopaminergic cells that occur with aging do not match those seen in PD /74, 75/. Furthermore, the amount of neuromelanin in the substantia nigra increases in old age but decreases in PD /76/.
Considerable evidence supports the view that older animals are more susceptible than younger animals to the neurotoxic effects of MPTP. Many studies have examined the effects of aging on MPTP-toxicity in mice, rats, and non-human primates /33, 77-97/. In rats and mice following systemic administration of MPTP, all indicators of neurotoxicity (mortality, cell loss in the substantia nigra, dopamine depletion, and motor signs) are increased at 12 directly into the brain, however, lack of increased toxicity in older animals indicates that old neurons are not intrinsically more susceptible than young neurons to this neurotoxin /94/. Aging is associated with an increased activity and expression of MAOB in the brain /87/. Because MAOB is the enzyme responsible for converting MPTP to MPP + , the conclusion is that an age-related increase in MAOB activity in the brain is the mechanism underlying the age-related increase in the susceptibility to systemically administered MPTP. 
GENE-ENVLRONMENT INTERACTIONS
The association among pesticides, MPTP, and PD led researchers to consider the possibility that genetic variability in xenobiotic metabolism may influence susceptibility to PD. Initially, the polymorphism in cytochrome P450 2D6 (debrisoquine hydroxylase) was investigated. Cytochrome P450 2D6 was of particular interest because it is involved in the detoxification of MPTP /111/ and in the metabolism of various pesticides. One early report /112/ stated that subjects with PD were significantly more likely than control subjects to be poor metabolizers of debrisoquine. Subsequently, many studies /I Π-Ι 16/ were carried out on the association between cytochrome P450 2D6 and PD and, more recently, these have focused on genetic variability in the CYP2D6 gene because this is not influenced by concomitant anti-parkinsonian drug therapy. In one large study and meta-analysis (1133 patients, 1950 controls), we found that the combined odds ratio for PD was significantly elevated for subjects with the poor-metabolizer genotype (OR 1.47, P=0.01) /113/. The association between CYP2D6 and PD remains controversial. Nevertheless, another study confirmed a higher frequency of the poor metabolizer genotype in cases of PD proven at autopsy /114/.
When searching for an association between polymorphic variability in xenobiotic metabolizing genes and PD, obviously the association will become more apparent when examining only those subjects who have been exposed to the causative neurotoxin /II5/. (This may not be the case if exposure to the xenobiotic is universal or if the polymorphism has an effect unrelated to xenobiotic metabolism.) In this respect, it is of note that subjects who have the poor metabolizer genotype of CYP2D6 and who reported past exposure to pesticides were more likely to develop PD associated with dementia symptoms / I 16/.
Other genes involved in xenobiotic metabolism have been studied. We found that the distribution of Pi class glutathione transferase (GSTP) polymorphisms was different in PD and control subjects, but only when analyzing subjects who reported past exposure to pesticides /117/. We found a similar association between pesticide exposure, genetic variability, and PD for zeta class glutathione transferase (GSTZ) /118/, but not for paraoxonase /119/. Glutathione transferases are important in the metabolism of quinones, a class of compounds that includes dopamine degradants and certain pesticides. NADPH:quinone oxidoreductases (NQO) are also involved in the metabolism of quinones and interestingly, the deletion of a promoter region sequence of the NQ02 gene is reportedly linked to PD (OR 3.463, Ρ < 0.0001) / 120/.
Polymorphisms in MAOB
have also been investigated /121-124/. MAOB is involved in the activation of MPTP and, in this respect, can be considered a xenobiotic-metabolizing enzyme. In addition, MAOB is involved with the metabolism of dopamine in a reaction that generates oxidative stress, providing another potential mechanism for its association with PD. We found that polymorphic variation in a (GT) n repeat is associated with PD in an Australian population /123/ but not in a Chinese population /124/. Polymorphic variability has been suggested to interact with smoking in altering susceptibility to PD /125/, an observation that we confirmed /126/. This view suggests an alternate gene-environment interaction for MAOB. Further research into gene-environment interactions is an important future area for PD research /127/. 
CONCLUSION
